Remission of HCV-associated glomerulonephritis with pegylated IFN and ribavirin therapy after liver transplantation: Case report and literature review

Maria Francesca Donato, Fabrizio Fabrizi, Giovanni Battista Fogazzi, Donata Cresseri, Patrizia Passerini, Paul Martin, Piergiorgio Messa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Hepatitis C virus infection is associated with a variety of extrahepatic disorders such as membrano-proliferative glomerulonephritis, which is generally due to cryoglobulinemia. Setting: We describe the case of one liver transplant recipient who received antiviral therapy (subcu-taneous administration of peg-IFN-alpha-2a 180 mcg weekly and oral ribavirin 200 mg thrice a day) for HCV-related membrano-proliferative glomerulonephritis. He presented normal kidney function, non-nephrotic proteinuria (2 g/24 h) and mild hematuria. Results: Urinary abnormalities disappeared within a few weeks after the initiation of antiviral therapy; however, combination antiviral therapy was not able to obtain viral clearance. After 11 months, IFN-therapy was interrupted and the patient continued low-dose ribavirin monotherapy (200 mg once per day) for one additional year- remission of proteinuria (<0.3 g/24 h) and hematuria persisted with intact kidney function. Although other mechanisms cannot be excluded, we suggest that ribavirin therapy was critically implicated in the remission of urinary abnormalities in our patient. The existing literature on the association between HCV-associated glomerulonephritis and therapy with ribavirin is reviewed. Conclusions: Antiviral therapy may be effective in patients with HCV-induced glomerulonephritis. Further evidence is needed to evaluate efficacy and safety of ribavirin monotherapy for HCV-related glomerulonephritis.

Original languageEnglish
Pages (from-to)63-68
Number of pages6
JournalInternational Journal of Artificial Organs
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Ribavirin
Glomerulonephritis
Liver
Liver Transplantation
Antiviral Agents
Transplants
Viruses
Hematuria
Proteinuria
Therapeutics
Kidney
Cryoglobulinemia
Virus Diseases
Hepacivirus
Safety

Keywords

  • Glomerulonephritis
  • HCV RNA
  • Hepatitis C
  • Liver transplantation
  • Ribavirin

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Remission of HCV-associated glomerulonephritis with pegylated IFN and ribavirin therapy after liver transplantation : Case report and literature review. / Donato, Maria Francesca; Fabrizi, Fabrizio; Fogazzi, Giovanni Battista; Cresseri, Donata; Passerini, Patrizia; Martin, Paul; Messa, Piergiorgio.

In: International Journal of Artificial Organs, Vol. 36, No. 1, 01.01.2013, p. 63-68.

Research output: Contribution to journalArticle

Donato, Maria Francesca ; Fabrizi, Fabrizio ; Fogazzi, Giovanni Battista ; Cresseri, Donata ; Passerini, Patrizia ; Martin, Paul ; Messa, Piergiorgio. / Remission of HCV-associated glomerulonephritis with pegylated IFN and ribavirin therapy after liver transplantation : Case report and literature review. In: International Journal of Artificial Organs. 2013 ; Vol. 36, No. 1. pp. 63-68.
@article{823b996373af4dc9a3384943fbe7a632,
title = "Remission of HCV-associated glomerulonephritis with pegylated IFN and ribavirin therapy after liver transplantation: Case report and literature review",
abstract = "Background: Hepatitis C virus infection is associated with a variety of extrahepatic disorders such as membrano-proliferative glomerulonephritis, which is generally due to cryoglobulinemia. Setting: We describe the case of one liver transplant recipient who received antiviral therapy (subcu-taneous administration of peg-IFN-alpha-2a 180 mcg weekly and oral ribavirin 200 mg thrice a day) for HCV-related membrano-proliferative glomerulonephritis. He presented normal kidney function, non-nephrotic proteinuria (2 g/24 h) and mild hematuria. Results: Urinary abnormalities disappeared within a few weeks after the initiation of antiviral therapy; however, combination antiviral therapy was not able to obtain viral clearance. After 11 months, IFN-therapy was interrupted and the patient continued low-dose ribavirin monotherapy (200 mg once per day) for one additional year- remission of proteinuria (<0.3 g/24 h) and hematuria persisted with intact kidney function. Although other mechanisms cannot be excluded, we suggest that ribavirin therapy was critically implicated in the remission of urinary abnormalities in our patient. The existing literature on the association between HCV-associated glomerulonephritis and therapy with ribavirin is reviewed. Conclusions: Antiviral therapy may be effective in patients with HCV-induced glomerulonephritis. Further evidence is needed to evaluate efficacy and safety of ribavirin monotherapy for HCV-related glomerulonephritis.",
keywords = "Glomerulonephritis, HCV RNA, Hepatitis C, Liver transplantation, Ribavirin",
author = "Donato, {Maria Francesca} and Fabrizio Fabrizi and Fogazzi, {Giovanni Battista} and Donata Cresseri and Patrizia Passerini and Paul Martin and Piergiorgio Messa",
year = "2013",
month = "1",
day = "1",
doi = "10.5301/ijao.5000166",
language = "English",
volume = "36",
pages = "63--68",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Remission of HCV-associated glomerulonephritis with pegylated IFN and ribavirin therapy after liver transplantation

T2 - Case report and literature review

AU - Donato, Maria Francesca

AU - Fabrizi, Fabrizio

AU - Fogazzi, Giovanni Battista

AU - Cresseri, Donata

AU - Passerini, Patrizia

AU - Martin, Paul

AU - Messa, Piergiorgio

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Hepatitis C virus infection is associated with a variety of extrahepatic disorders such as membrano-proliferative glomerulonephritis, which is generally due to cryoglobulinemia. Setting: We describe the case of one liver transplant recipient who received antiviral therapy (subcu-taneous administration of peg-IFN-alpha-2a 180 mcg weekly and oral ribavirin 200 mg thrice a day) for HCV-related membrano-proliferative glomerulonephritis. He presented normal kidney function, non-nephrotic proteinuria (2 g/24 h) and mild hematuria. Results: Urinary abnormalities disappeared within a few weeks after the initiation of antiviral therapy; however, combination antiviral therapy was not able to obtain viral clearance. After 11 months, IFN-therapy was interrupted and the patient continued low-dose ribavirin monotherapy (200 mg once per day) for one additional year- remission of proteinuria (<0.3 g/24 h) and hematuria persisted with intact kidney function. Although other mechanisms cannot be excluded, we suggest that ribavirin therapy was critically implicated in the remission of urinary abnormalities in our patient. The existing literature on the association between HCV-associated glomerulonephritis and therapy with ribavirin is reviewed. Conclusions: Antiviral therapy may be effective in patients with HCV-induced glomerulonephritis. Further evidence is needed to evaluate efficacy and safety of ribavirin monotherapy for HCV-related glomerulonephritis.

AB - Background: Hepatitis C virus infection is associated with a variety of extrahepatic disorders such as membrano-proliferative glomerulonephritis, which is generally due to cryoglobulinemia. Setting: We describe the case of one liver transplant recipient who received antiviral therapy (subcu-taneous administration of peg-IFN-alpha-2a 180 mcg weekly and oral ribavirin 200 mg thrice a day) for HCV-related membrano-proliferative glomerulonephritis. He presented normal kidney function, non-nephrotic proteinuria (2 g/24 h) and mild hematuria. Results: Urinary abnormalities disappeared within a few weeks after the initiation of antiviral therapy; however, combination antiviral therapy was not able to obtain viral clearance. After 11 months, IFN-therapy was interrupted and the patient continued low-dose ribavirin monotherapy (200 mg once per day) for one additional year- remission of proteinuria (<0.3 g/24 h) and hematuria persisted with intact kidney function. Although other mechanisms cannot be excluded, we suggest that ribavirin therapy was critically implicated in the remission of urinary abnormalities in our patient. The existing literature on the association between HCV-associated glomerulonephritis and therapy with ribavirin is reviewed. Conclusions: Antiviral therapy may be effective in patients with HCV-induced glomerulonephritis. Further evidence is needed to evaluate efficacy and safety of ribavirin monotherapy for HCV-related glomerulonephritis.

KW - Glomerulonephritis

KW - HCV RNA

KW - Hepatitis C

KW - Liver transplantation

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84874221258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874221258&partnerID=8YFLogxK

U2 - 10.5301/ijao.5000166

DO - 10.5301/ijao.5000166

M3 - Article

C2 - 23280083

AN - SCOPUS:84874221258

VL - 36

SP - 63

EP - 68

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 1

ER -